Takeda launches CINRYZE in India for hereditary angioedema patients
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Patients with moderate or elevated risk in the test should immediately consult a cardiologist for further diagnosis and workup
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
To set up 50 lifestyle modification centres across the UAE in the next 24 months
The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
Survey findings released in advance of World Lupus Day on May 10
Nocria’s hand-held device uses gentle, controlled puffs of air in the ears for treating migraine attacks
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Subscribe To Our Newsletter & Stay Updated